Table 3

Results from base-case analyses
a: Overall effects [cohort of 1 million individuals not discounted]
Number of HZ-cases Costs of treatment (€) Costs of vaccination (€) Total costs (€) BCR*
Status quo 284,768 127,978,000 - 127,978,000
Vaccination scenario 264,977 117,948,913 29,496,000 147,444,913 0.34
b: Number needed to vaccinate (NNV)
Avoiding one HZ-case 10
Avoiding one PHN-case 144
Gaining one QALY 195
c: Costs and effects in both scenarios of the model
Not discounted Costs (€) Effects [QALY] Costs/Effects ICER
Status quo 127.98 29.2747 4.3716
Vaccination scenario 147.44 29.2757 5.0364 19,002
Discounted
Status quo 82.80 18.8569 4.3911
Vaccination scenario 98.64 18.8574 5.2307 28,146

*Benefit-Cost ratio; , Euro in 2010 price levels.ICER, incremental cost-effectiveness ratio; HZ, herpes zoster; PHN, postherpetic neuralgia; QALY, quality adjusted life-year.

Ultsch et al.

Ultsch et al. BMC Health Services Research 2013 13:359   doi:10.1186/1472-6963-13-359

Open Data